Regenxbio Inc (RGNX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.03 (-2.25%), Market cap $0.34B, 52-week low–high $5.65 ~ $15.98.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the com
Financial statements, price targets, institutional (13F) holdings and related news for Regenxbio Inc are updated in real time on BlackAll Trade.
Regenxbio Inc trades at $8.03 (-2.25%). Real-time quotes and charts are available on BlackAll Trade.
Regenxbio Inc has a market cap of about $0.34B.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates ar